Clinical Trial Update: Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study [Phase 4]

View source ↗

Summary

Phase 4 post-marketing study of Vedolizumab-4002 investigating drug–drug interactions has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Vedolizumab-4002

Snippet

Sponsor: Takeda | Conditions: Colitis, Ulcerative, Crohn Disease | Phase 4 | Status: WITHDRAWN